Mice with thyroid-specific expression of oncogenic BRAF (Tg-Braf) develop papillary thyroid cancers (PTCs) that are locally invasive and have well-defined foci of poorly differentiated thyroid carcinoma (PDTC). To investigate the PTC-PDTC progression, we performed a microarray analysis using RNA from paired samples of PDTC and PTC collected from the same animals by laser capture microdissection. Analysis of eight paired samples revealed a profound deregulation of genes involved in cell adhesion and intracellular junctions, with changes consistent with an epithelial-mesenchymal transition (EMT). This was confirmed by immunohistochemistry, as vimentin expression was increased and E-cadherin lost in PDTC compared with adjacent PTC. Moreover, PDTC stained positively for phospho-Smad2, suggesting a role for transforming growth factor (TGF)b in mediating this process. Accordingly, TGFb-induced EMT in primary cultures of thyroid cells from Tg-Braf mice, whereas wild-type thyroid cells retained their epithelial features. TGFb-induced Smad2 phosphorylation, transcriptional activity and induction of EMT required mitogen-activated protein kinase (MAPK) pathway activation in Tg-Braf thyrocytes. Hence, tumor initiation by oncogenic BRAF renders thyroid cells susceptible to TGFb-induced EMT, through a MAPK-dependent process.
Introduction
The BRAF T1799A mutation, which encodes BRAF V600E , is the most common genetic event in papillary thyroid cancers (PTCs) Soares et al., 2003; Xing, 2005) . PTCs with BRAF mutations have a higher prevalence of extrathyroidal invasion, lymph node metastases, and have a higher rate of recurrence and decreased survival (Soares et al., 2003; Elisei et al., 2008) . BRAF V600E mutation has also been demonstrated to predict a worse outcome in poorly differentiated thyroid cancers (PDTCs) (Ricarte-Filho et al., 2009) .
The evidence supporting a stepwise progression from PTC to PDTC is based primarily on the observation that distinct regions of PTC and PDTC (or anaplastic thyroid cancer (ATC)) frequently coexist within the same tumor (Namba et al., 2003; Nikiforova et al., 2003; Ricarte-Filho et al., 2009) . The histopathological definition of human PDTC is controversial, which has confounded the interpretation of genetic and gene expression studies of this clinical entity. Mutations of P53 and CTNNB1 are found in anaplastic thyroid cancers (Fagin et al., 1993) , and in a small proportion of PDTC. PDTC with BRAF mutations are also associated with mutations of PIK3CA or AKT1, primarily in metastases with high metabolic activity (Ricarte-Filho et al., 2009) . Most studies of PDTC compared small numbers of PTC and PDTC samples from different patients, and thus had a limited resolution to identify events leading to phenotypic progression.
Tg-Braf mice overexpress BRAF V600E in thyroid cells, under the regulatory control of the thyroglobulin (Tg) gene promoter (Knauf et al., 2005) . These mice develop invasive PTCs with high penetrance and short latency, which progress to PDTCs later in life, providing a model to explore mechanisms of disease progression. To this end, we analyzed expression profiles of paired PTC-PDTC foci to identify possible triggering events responsible for the PTC to PDTC transition. Our data point to an important role for transforming growth factor (TGF)b in this process, through induction of epithelialto-mesenchymal transition (EMT). Oncogenic BRAF induces TGFb1 secretion in vitro, and a TGFb-driven autocrine loop may mediate in part the effects of the oncoprotein on the activity of the sodium iodide transporter (NIS), as well as on cell migration, invasiveness and EMT (Riesco-Eizaguirre et al., 2009) . The studies reported here indicate thyroid cancer cells that develop in vivo following BRAF activation are susceptible to undergo EMT in response to TGFb, and that this requires concomitant constitutive activation of mitogenactivated protein kinase (MAPK), and that these two pathways converge on Smads to modulate TGFb transcriptional output.
Results
Gene expression profiles of PTC and PDTC from Tg-Braf mice Tg-Braf mice develop PTC by 3 weeks of age, and by 5 months virtually all cancers are locally invasive. At this time, approximately 50% have distinct focal areas of PDTC (Knauf et al., 2005) , which are characterized by spindle-shaped cells with a solid pattern of growth and increased number of mitotic figures ( Figure 1A ). To identify gene expression changes involved in the transition from PTC to PDTC, we used laser capture microdissection to isolate cells from individual poorly differentiated foci and a corresponding area of PTC from eight Tg-Braf mice ( Figure 1B) . RNA was isolated from the laser captured cells of PTC and PDTC paired samples, amplified, labeled with Cy5 or Cy3, and co-hybridized to the microarray chips. This identified 1630 genes with significant expression changes (Po0.05, false discovery rateo0.1). Of these, 955 gene products decreased and 675 increased in the PDTC compared with the PTC. To identify signaling pathways that may mediate or contribute to these expression changes we used LRPath (Sartor et al., 2009 ) to compare our data set with the following databases: Gene Ontology, MeSH, Metabolite, KEGG pathways, Biocarta pathways, Pfam, Panther pathways, OMIM, Cytoband and DrugBank, as defined in the functional enrichment program ConceptGen (Sartor et al., 2010) . Representative concept categories that were found to be significantly represented (Po0.001 and FDRo0.01) are listed in Supplementary  Tables 1 and 2. EMT occurs during progression of PTC to PDTC The main concept categories altered in the PTC-PDTC transition included 'extracellular matrix', 'cell adhesion', 'tight junctions' and 'apicolateral plasma membrane'. Genes involved in tight junctions, desmosomes and adherent junction proteins were significantly downregulated, whereas expression of intermediate filament and basement membrane genes was increased (Table 1) . These expression changes indicate that an EMT occurred during progression from PTC to PDTC. To confirm this, a second set of five thyroids from Tg-Braf animals containing foci of PDTC were stained for E-cadherin and vimentin ( Figure 2a ). All foci of PDTC lacked E-cadherin staining, and stained strongly for vimentin, confirming the microarray results, and the mesenchymal phenotype of PDTC. By contrast, regions of PTC stained strongly for E-cadherin, and weakly or not at all for vimentin.
Marked increase in pSmad2 in PDTC
In other model systems, induction of EMT involves activation of TGFb signaling pathways (reviewed in (Xu et al., 2009) ). Expression of BRAF V600E in the well-differentiated thyroid cell line PCCL3 was recently reported to increase secretion of TGFb1 (Riesco-Eizaguirre et al., 2009) . We found that TGFb1 expression was increased 1.7-fold (P ¼ 0.002) in Tg-Braf thyroids compared with normal by RT-PCR (Figure 2d) . A further increase in TGFb signaling in PDTC compared with PTC was supported by ConceptGen analysis (Sartor et al., 2010) , which found that 123 genes that were differentially regulated in the PDTC also had expression changes in immortalized ovarian surface epithelial cells treated with TGFb (P ¼ 7.6 Â 10
À11
). To provide an independent measure of TGFb pathway activation in PDTC, we performed immunohistochemistry for phospho (S465/ 467) Smad2, and found a marked increase in pSmad2 positive cells in PDTC compared with adjacent PTC (Figure 2a) . Interestingly, tumor-associated macrophages (TAMs), which are a known source of TGFb (Savage et al., 2008) , are present in high numbers in human PDTC and anaplastic thyroid cancers (Ryder et al., 2008) . As shown in Figure 2b , TAM abundance was also markedly increased in regions of PDTC compared with PTC ( Figure 2b ). To further investigate the source of the (ii, iv, vi, viii) . Images in panels (vii, viii) were acquired using the Nuance imaging system, which converted the hematoxylin blue counter stain to red, and the brown pSmad stain to blue, to allow better distinction of pSmad from the counter stain. (Figure 2d ). The abundance of TGFb is also regulated by proteolytic cleavage of its latent form, but this could not be resolved in this model.
TGFb-induced EMT requires mitogen-activated protein kinase kinase (MEK) activation in Tg-Braf thyrocytes
We next examined whether TGFb was sufficient to induce EMT in primary cultures of Tg-Braf PTCs. Incubation with TGFb induced a spindle-shape morphology in Tg-Braf thyroid cells (Figure 3a ), but not wild-type thyroid cells (Figure 3b ), which was associated with increased vimentin and loss of E-cadherin immunostaining. The vimentin ( þ ) E-cadherin (À) cells were confirmed to be epithelial by staining for cytokeratin. Accordingly, vimentin and E-cadherin mRNA levels were regulated reciprocally by TGFb (Figure 3c ). Expression of the E-cadherin repressors Snail 1, Zeb1 and Zeb2 was increased, suggesting that these genes may help mediate induction of EMT by TGFb in Tg-Braf thyroid cancer cells. By contrast, TGFb did not evoke changes in vimentin and E-cadherin expression or localization in wild-type thyroid cells (Figure 3b ). This suggests that constitutive MAPK activation may be required for TGFb to induce EMT in cells transformed by oncogenic Braf. Consistent with this, addition of the MEK inhibitor U0126 blunted the TGFb-induced EMT, as shown by the lack of effect on cell morphology and unchanged vimentin or E-cadherin localization (Figure 3a ).
TGFb-induced Smad2 phosphorylation and transcriptional activity is MEK dependent
TGFb has been shown to activate MAPK in a Smadindependent manner (Derynck and Zhang, 2003; Lee et al., 2007) . In turn, MAPK can modulate TGFb-induced signaling through phosphorylation of the MH1 or linker regions of Smad2 or 3 (Wrighton et al., 2009) . As shown Tg-Braf (a) or wild-type (b) mice were plated into chamber slides coated with collagen and incubated for 48 h. Cells were then incubated in the absence or presence of TGFb (10 ng/ml) with or without U0126 (25 mM) for 6 days, with a medium change every 2 days. Cells in the left panels of (a, b) were co-stained for E-cadherin (green) and cytokeratin (red). Cells in the right panel were stained for vimentin (green) and cytokeratin (red). Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI) (blue). (c) Tg-Braf thyroid primary cells were plated into CellBind plates and incubated for 48 h. Cells were then incubated in the absence or presence of TGFb for 10 days in serum-free medium. RNA was isolated and used in quantitative RT-PCR reactions for the indicated transcripts.
in Figure 4a , treatment of primary cultures of Tg-Braf thyrocytes with TGFb resulted in increased levels of phospho (S465/467) Smad2, C-terminal sites known to be phosphorylated following activation of the TGFb receptor, and to be required for its transcriptional function. By contrast, phosphorylation of threonine 8 in the MH1 region of Smad2 was not regulated by TGFb. Pretreatment with a MEK inhibitor for 3 h decreased p(T8) Smad2, and blunted the TGFb-induced increase in p(S465/467)Smad2. The inhibitory effects of U0126 on TGFb-induced Smad2 (S465/467) phosphorylation were confirmed in the mBraf-p53 immortalized cell line created from a transgenic mouse with thyroid-specific expression of Braf V600E and loss of p53. Here, pretreatment with the MEK inhibitor blunted TGFb-induced Smad phospho S465/467 in a time-dependent manner ( Figure 4b ). Total Smad levels were higher in cancer cells than in wild-type thyrocytes (Figure 4c ). After 24-h incubation with MEK inhibitor, total Smad levels were significantly reduced. Although the effects of MEK inhibition of Smad phosphorylation precede the changes in total Smad protein, it is important to note that Smad stability is also a recognized mechanism to regulate the output of the TGFb signaling pathway ( (Lin et al., 2000; Seo et al., 2004) , reviewed in (Inoue and Imamura, 2008) ). In our model, the lower levels of Smad2 protein after prolonged treatment with U0126 are likely due to posttranscriptional events, as Smad2 mRNA levels were not decreased (data not shown).
In many cell contexts, ERK activation has been associated with inhibitory effects on TGFb signaling. Our results, by contrast, suggest that constitutive activation of the MAPK pathway is required for optimal TGFb signaling in mouse thyroid cancer cells induced by Braf. To confirm this, we determined the effects of MEK inhibition on the activity of the TGFb-Smad transcriptional reporter 3TP-Lux. TGFb induced far greater 3TP-Lux reporter activity in Tg-Braf (sevenfold) compared with wild-type thyroid cells (twofold) (Figures  4d and e) . MEK inhibition blocked TGFb-induced 3TP-Lux reporter activity in both Tg-Braf and wild-type thyroid primary cultures.
EMT in human PTC progression to undifferentiated thyroid cancers To investigate whether EMT also occurs in progression of human thyroid cancers, we immunostained a panel of differentiated and undifferentiated thyroids carcinoma tissue microarrays for E-cadherin. Consistent with other (a) Tg-Braf thyroid cells were plated into primary culture in CellBind plates and incubated for 48 h. Cells were then incubated in the absence or presence of U0126 (25 mM) for 3 h. TGFb (10 ng/ml) was then added for 1 h. Protein lysates were prepared and subjected to western blotting for the indicated proteins.
(b) Immortalized mBraf-p53 cells were incubated in the absence or presence of U0126 (25 mM) for 1-3 h. TGFb (10 ng/ml) was then added for 1 h. Protein lysates were prepared and subjected to western blotting for the indicated proteins. (c) Tg-Braf or wild-type thyroid cells were plated into primary culture in CellBind plates and incubated for 48 h. Cells were then incubated in the absence or presence of TGFb (10 ng/ml) with or without U0126 (25 ı`M) for 24 h. Protein lysates were prepared and subjected to western blotting for the indicated proteins. (d, e) Primary thyroid cells from wild-type (d) or Tg-Braf (e) mice were plated into 24-well plates coated with collagen and incubated for 48 h. Cells were then co-transfected with 3TP-lux and cytomegalovirus (CMV)-renilla lucerifase. At 16 h after transfection, the medium was changed to medium with or without TGFb (10 ng/ml) and U0126 (25 mM) and incubated for 36 h. Firefly and renilla lucerifase activity were then determined. Bars represent fold-change from untreated cells in firefly lucerifase activity after normalizing for differences in renilla lucerifase activity, and subtracting background activity as determined in cells transfected with pGL3-basic.
reports we found that most of the undifferentiated thyroid carcinoma specimens (14/18, 78%) lost membranous E-cadherin. The four undifferentiated carcinomas with membranous staining were squamous cell carcinomas or had squamoid features, while all the anaplastic carcinomas showing mesenchymal differentiation were negative for E-cadherin ( Figure 5 ). By contrast, almost all well-differentiated papillary thyroid carcinomas (32/33, 97%) maintained membranous staining for E-cadherin ( Figure 5 ). The difference in staining for E-cadherin between differentiated and undifferentiated tumors was significant (Po0.0001).
To further explore the association of oncogenic BRAF with EMT, we stained an additional seven ATC known to harbor BRAF mutations: four with mesenchymal differentiation, two with squamoid features and one with mixed squamoid and mesenchymal features. The BRAF
V600E
( þ ) ATC with mesenchymal differentiation did not stain for E-cadherin, whereas those with squamoid features had membrane staining for E-cadherin. This indicates that loss of E-cadherin (that is, EMT) is tightly associated with mesenchymal differentiation. However, the presence of BRAF V600E does not appear to predict whether an ATC will have squamoid or mesenchymal features. We were not able to optimize phospho (S465/467) Smad2 immunohistochemistry on human formalinfixed, paraffin-embedded sections to determine whether the EMT in undifferentiated carcinomas was associated with increased TGFb signaling. However, a comparison of expression arrays from human BRAF V600E ( þ ) PTC and ATC identified 1943 genes that were differentially regulated in the ATC compared with PTC, which included increased expression of TGFbI and decreased expression of Smad6, a negative regulator of TGFb signaling. The activation of the TGFb signaling pathway is also supported by ConceptGen analysis, which found that 177 of the differentially expressed genes were also altered in immortalized ovarian surface epithelial cells treated with TGFb (P ¼ 3.4 Â 10
À11
). Other representative concept categories identified by LRPath analysis of genes differentially expressed between BRAF V600E ( þ ) human PTC and ATC are listed in Supplementary Tables 1 and 3 . Most were related to cell division, which is consistent with the high mitotic rate of ATC. Interestingly, a number of concept categories were common to both mouse and human thyroid tumor progression (Supplementary Table 4 ). These include the categories 'extracellular matrix', 'tight junctions' and 'apicolateral plasma membrane', further supporting EMT as a key event in progression of Braf V600E -mutant PTC to undifferentiated cancers in mice and humans.
Discussion
Here, we aimed to identify events associated with thyroid cancer progression in a mouse model of tumorigenesis induced by Braf
V600E
. The expression profile of PDTC showed an unequivocal signature of EMT as compared with paired samples of PTC. We believe that the PDTC arising in Tg-Braf mice represent a bona fide progression event. Thus, they are unlikely to have arisen de novo from a distinct thyroid progenitor cell (that is, without traversing through a well-differentiated phase), in which case they would have manifested earlier because of their higher mitotic rate. EMT involves changes whereby epithelial cells disassemble their junctional structures, express mesenchymal proteins, remodel their extracellular matrix, lose polarity and become more migratory. This phenotypic switch is a key process in development, and also occurs during tissue regeneration and organ fibrosis, usually in response to an inflammatory process (reviewed in Kalluri and Weinberg, 2009 ). Cancer cells use this property of epithelial cells to enhance their invasive and metastatic potential and render them more resistant to apoptotic cues. Accordingly, cells within the invasive front of human thyroid cancers have gene expression changes consistent with EMT when compared with cells in the central part of the tumor (Vasko et al., 2007) . In addition, loss of E-cadherin, a hallmark of EMT, is a marker of progression from differentiated to undifferentiated thyroid cancers (Wiseman et al., 2007) , a finding that we confirmed in our tissue microarray experiment. Moreover, a transcriptomic comparison of differentiated and dedifferentiated thyroid tumors found E-cadherin to be among the top genes that distinguished between these histotypes (Montero-Conde et al., 2008) .
The full spectrum of triggering events that contribute to EMT in tumor cells is not completely understood. Alterations that occur during the course of primary tumor formation may sensitize them to EMT-inducing signals that arise during tumor progression, including expression of growth factors, such as hepatocyte growth factor, epidermal growth factor, platelet-derived growth factor and TGFb (Jechlinger et al., 2002; Peinado et al., 2007; Weinberg, 2008) . The expression profile of the paired specimens did not yield a clear signature of activation of any of these growth factors or cytokines, with the exception of TGFb, which scored robustly in one of the data sets we used to interrogate the arrays. The pattern of genes activated in response to TGFb is notoriously variable because of the presence of distinct transcriptional partners of Smad in different cell types and conditions, which define synexpression groups that are highly context-dependent (Gomis et al., 2006; Massague, 2008) , and which may account for the lack of uniformity of TGFb expression signatures between databases.
The presence of nuclear pSmad staining in PDTC provides evidence for a stage-specific activation of TGFb. There was a marked increase in the number of TAMs in PDTCs, which express high levels of TGFb (Figure 2d , Savage et al., 2008) . As is the case for other epithelial lineages, TGFb is not by itself sufficient to convert normal thyroid cells to a mesenchymal phenotype. TGFb inhibits thyroid cell growth induced by thyroid stimulating hormone or growth factors in non-transformed rat and normal porcine thyroid cells, respectively (Morris III et al., 1988; Tsushima et al., 1988) . The proposed mechanism of growth impairment by TGFb is through interference with the association of the cyclin D3/cdk4 holoenzyme with p27 kip1 (Depoortere et al., 2000) .
Of note, a correlation between TGFb signaling and EMT was also found in human PDTC and ATC (Montero-Conde et al., 2008) . The execution of the EMT program in response to TGFb depends on priming events occurring during tumor microevolution (reviewed in (Tse and Kalluri, 2007) ). BRAF-induced thyroid cancer is driven primarily by constitutive activation of the classical MAPK pathway, as demonstrated by the sensitivity of BRAF-mutated thyroid cancer cell lines to MEK inhibitors (Ball et al., 2007; Leboeuf et al., 2008) . Our data in primary cultures of PTC cells from Tg-Braf mice shows that they are already primed for TGFbinduction of EMT, and that this is mediated via MAPK activation, since the process is prevented by treatment with a MEK inhibitor. The role of TGFb as a triggering event for EMT has also been demonstrated in immortalized rat thyroid PCCL3 cells overexpressing oncogenic Braf (Riesco-Eizaguirre et al., 2009) . In these cells, TGFb-induced EMT was also blocked by MEK inhibition. This has also been reported in the mammary gland epithelial cell line NMuMG, in which EMT was blocked by inhibition of MEK, but in contrast to our results this was not associated with changes in TGFbinduced Smad phosphorylation (Xie et al., 2004) .
Smads are potential convergence nodes for TGFb and MAPK signaling. Smad2 is phosphorylated by ERK at multiple sites in the hinge domain (T220, S245 and S250) and at T8 in the MH1 domain (Funaba et al., 2002; Wrighton et al., 2009) . The functional consequences of MAPK phosphorylation of Smads appears to be context-dependent, although the role of each individual site in different cell types has not been carefully mapped. Whereas most of the ERK substrates in the hinge domain are also phosphorylated by multiple other kinases, T8 phosphorylation is largely controlled by ERK, and therefore serves as a useful readout of the activity of MAPK. Accordingly, pT8 Smad2 was markedly increased in thyroid cells from Tg-Braf mice, and inhibited by treatment with UO126. The canonical TGFb receptor Smad phosphorylation sites at the C terminus SXS motifs track closely with transcriptional activation. Interestingly, TGFb-induced SXS phosphorylation was decreased by inhibition of MEK activity in both wild-type and Tg-Braf cells, as did Smad transcriptional output.
As reported in other cancer lineages, the ultimate effects of TGFb on thyroid cell growth may vary according to the stage of tumor development (Tang et al., 2003) . During early stages of clonal expansion, cells may need to bypass growth inhibitory and apoptotic signals mediated by TGFb. This can be done through a loss of the core pathway (that is, TGFb receptor mutations) or selective amputation of the growth inhibitory/apoptotic arm of the pathway. In the thyroid, this has been proposed to be mediated through a variety of mechanisms, including NF-kB activation (Bravo et al., 2003) . In some cancers, when the core TGFb signaling pathway remains intact, the tumor can utilize the pro-tumor attributes of the TGFb pathway to promote progression (that is, autocrine mitogens, pro-metastatic cytokines, immune evasion and EMT). For example, a TGFb-response signature was found to be associated with lung metastases in estrogen receptor-negative breast cancers (Padua et al., 2008) . The data reported in this spontaneously developing model of thyroid cancer progression shows that the growth inhibitory and pro-apoptotic action of TGFb, if present, are bypassed via mechanisms that leave the core TGFb signaling pathway intact, allowing at least some components of TGFb signaling to be engaged during disease progression and be co-opted to promote EMT. Taken together with recent evidence that TGFb may contribute to the impairment of iodine transport in thyroid cells induced by oncogenic Braf (Riesco-Eizaguirre et al., 2009), a legitimate case can now be made that targeting TGFb signaling in advanced thyroid cancers may be of therapeutic benefit.
Materials and methods
Experimental animals Tg-Braf mice, which express Braf V600E under the control of the bovine Tg promoter, have been described (Knauf et al., 2005) , and were the primary model used in this study. LSL-Braf V600E / TPO-Cre mice, which harbor a latent oncogenic Braf knock-in allele activated in thyroid cells via Cre-mediated recombination (Franco et al., 2011) , were crossed with ROSA26-EGFP f/f mice (Mao et al., 2001) resulting in expression of green fluorescent protein in only the Braf-transformed thyroid cells, which allowed fluorescence-activated cell sorting analysis of thyroid cancer and stromal cell sub-populations. All animal experiments were approved by the Institutional Animal Care and Use Committees of the University of Cincinnati and Memorial Sloan Kettering Cancer Center.
Thyroid collection and laser capture microdissection Animals were euthanized with CO 2 and thyroids collected and immediately frozen in Optimal Cutting Temperature compound. Hematoxilin and eosin-stained frozen sections were examined by a thyroid pathologist (YEN) for identification of discrete foci of well-differentiated PTC and PDTC. Slides were stained with HistoGene laser capture microdissection Frozen Section Staining Kit (Arcturus Bioscience, Mountain View, CA, USA) and cells from the PDTC focus and a representative Primary cultures of thyroid cells Thyroid lobes were isolated, washed with 1 Â phosphatebuffered saline (PBS) and then with digestion medium (MEM þ 112 U/ml type I collagenase, 1.2 U/ml dispase and penicillin-streptomycin). The thyroids were then minced and incubated in digestion medium for 1 h at 37 1C and washed with growth medium consisting of Coon's modified F12 medium containing 2 mIU/ml bovine TSH, 20 mg/ml insulin, 10 g/ml apo-transferrin, 2 nM hydrocortisone, 3% fetal bovine serum, 0.5% bovine brain extract (Hammond Cell Tech, Windsor, CA, USA), penicillin and streptomycin. Cells were resuspended and plated into CellBind plates (Corning Inc., Lowell, MA, USA) or collagen-coated chamber slides. The thyroid cancer cell line is an immortalized murine thyroid cancer cell line that was created from a transgenic mouse with thyroid-specific expression of Braf V600E and loss of p53. mBrafp53 cells were grown in Coon's modified F12 medium containing 5% fetal bovine serum, 0.5% bovine brain extract (Hammond Cell Tech), penicillin and streptomycin.
Isolation of TAMs and thyroid cancers cells
Thyroid lobes from LSL-Braf V600E /TPO-Cre/ROSA26-EGFP f/f were washed with 1 Â PBS and then with digestion medium (MEM þ 112 U/ml type I collagenase, 1.2 U/ml dispase and penicillin-streptomycin). The thyroids were then minced and incubated in digestion medium for 2 h at 37 1C and washed with Coon's modified F12 medium containing 5% fetal bovine serum and penicillin and streptomycin. Cells were blocked with Fc-receptor and then stained with APC-conjugated rat antiCD11b (BD Biosciences, San Jose, CA, USA, cat# 553312), a molecular marker of macrophages. The TAMs and green fluorescent protein-positive thyroid cancer cells were isolated by flow cytometry and RNA isolated from the two cell populations using PicoPure RNA Isolation Kit (Arcturus Bioscience). Quantitative reverse transcriptase-PCR was performed as described below.
Western blotting
Thyroid cell primary cultures were incubated in CellBind plates with growth medium containing the indicated concentration of TGFb and U0126. Cells were then washed with icecold PBS, and harvested by scraping and centrifugation (1000 Â g for 4 min at 4 1C). The cell pellets were resuspended in a lysis buffer consisting of 10 mM Tris-HCl [pH 7.5], 5.0 mM ETDA, 4.0 mM EGTA, 1% Triton X-100, protease inhibitor cocktail (Sigma, St Louis, MO, USA), phosphatase inhibitor cocktail A & B (Sigma) and cells lysed by passing through a p200 tip, and cell debris removed by centrifugation. The supernatant was collected and the protein concentration determined using MicroBCA kit (Thermo Fisher Scientific, Rockford, IL, USA). Fifty micrograms of protein lysate was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinyl difluoride membranes. The membranes were probed with the indicated antibody and the target protein detected by incubating with species-specific horseradish peroxidase-conjugated immunoglobulin (Ig)G's and then with enhanced chemiluminescence reagent (Amersham Biosciences Corp., Piscataway, NJ, USA). Images were captured using the LAS4000 (Fujifilm Medical Systems, Stamford, CT, USA). The following antibodies were used phospho (Thr202/Tyr204) ERK1/2 (4376), ERK1/2 (4695), a/b-tubulin (2148) and phospho (Ser465/467) Smad2 from Cell Signaling; Smad2/3 (sc-8332) from Santa Cruz (Santa Cruz, CA, USA); Smad2 (ab63576) and phospho(T8)-Smad2/3 (ab63399) from Abcam.
Quantitative RT-PCR RNA was isolated from cells using Prepease RNA spin kit (USB Corporation, Cleveland, OH, USA). Reverse transcription and quantitative PCR was performed using the Superscript III First-Strand Synthesis system (Invitrogen, Carlsbad, CA, USA) and Fast SYBR Green Master Mix as directed by the manufacturer (Applied Biosystems Inc., Foster City, CA, USA), respectively (see Supplementary Table 5 for primer pair sequences). The CT value was used to calculate the b-actinnormalized expression of the different mRNAs using the Q-Gene program (Muller et al., 2002) .
3TP-Lux promoter assay
Primary cultures of thyroid cells from Tg-Braf and wild-type mice were incubated in growth medium until B80% confluent, and then transfected with cytomegalovirus-Renilla and either 3TP-Lux, pGL3-basic or pGL3-control using Fugene6 (Roche, Indianapolis, IN, USA). The TGFb-responsive 3TP-Lux construct contains three repeats of a 12-O-tetradecanoylphorbol 13-acetate responsive element plus the plasminogen activator inhibitor promoter linked to a luciferase reporter gene (Wrana et al., 1992) . Luciferase activity was determined using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). Firefly luciferase activity was normalized to cytomegalovirus-Renilla and subtracted from normalized luciferase activity in cells transfected with pGL3-Basic.
Immunofluorescence cytochemistry Tg-Braf and wild-type thyroid primary culture cells were plated onto collagen-coated chamber slides and incubated for 2-3 days. Cells were then changed to growth medium with or without TGFb and the indicated reagents for 6 days. Cells were then washed with ice-cold PBS and fixed in À20 1C methanol/acetone (1:1) for 4 min. Slides were then washed, incubated in PBS containing 10% goat serum and 0.1% Triton X-100 for 30 min and then in PBS with 1% goat serum and 0.05% Triton X-100 with the indicated primary antibodies for 2 h. After washing, slides were then incubated for 30 min with Alexa 488 and Alexa 647 -conjugated goat anti-mouse and anti-rabbit antibodies, respectively. The slides were then washed and the nuclei stained with 4,6-diamidino-2-phenylindole. Images were captured using Nikon Eclipse TE2000 (Nikon Instruments Inc., Melville, NY, USA). The following antibodies were used mouse anti-Ecadherin (610182) from BD Biosciences, mouse anti-vimentin (V5255) from Sigma and rabbit anti-cytokeratin (Z0622) from Dako (Carpinteria, CA, USA).
